etrials Adds Three New Trials for Top Ten Pharmaceutical Clients Company Supplies Patient Diary Technology to Over 4,000 New Patients
etrials Worldwide, Inc., the first company to offer fully integrated, easy-to-use eClinical software for the clinical trial process, today announced that it has added three new studies for top ten pharmaceutical companies. All three trials will use etrials' electronic patient diary technology on handheld devices (PDAs) to electronically capture patient reported outcomes (ePRO).
etrials Worldwide, Inc., the first company to offer fully integrated, easy-to-use eClinical software for the clinical trial process, today announced that it has added three new studies for top ten pharmaceutical companies. All three trials will use etrials' electronic patient diary technology on handheld devices (PDAs) to electronically capture patient reported outcomes (ePRO).
Two of the new studies are Phase III, women's health trials which will include 300 sites and approximately 4,000 patients. The third new trial is a Phase IIIb Neurology study which will include 20 sites and over 300 patients. etrials? ePRO devices will be distributed to patients participating in the studies to record and submit trial data remotely as well as used for site-based collection of data.
"As more emphasis is placed on faster access to critical patient data we have seen many of the top pharmaceutical companies making great strides in implementing eClinical technology in a variety of studies, across multiple trials and in all therapeutic areas," said John Cline, CEO of etrials. "Having the opportunity to work with many of the top ten pharmaceutical companies enables etrials to further demonstrate its unique ability to offer fully integrated and easy-to-use technology and the important efficiencies gained through the use of eClinical technology."
About etrials Worldwide, Inc.
etrials is a software and services company dedicated to making eClinical easy. We are the first company to offer a fully integrated suite of eClinical software including electronic data capture (EDC), electronic patient reported outcomes (ePRO), interactive voice response (IVR) and analytics to support the entire clinical trial process, from collection and cleaning to the integration and review of data. Our expertise includes studies from Phase I to post-approval for pharmaceutical, biotechnology and clinical research organizations. To date, our team of professionals has participated in over 450 clinical trials in more than 50 different countries.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease
February 25th 2025Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) achieved higher rates of clinical remission compared to placebo in the advanced therapy-experienced subgroup.
